Type your tag names separated by a space and hit enter

tafluprost

General

Pronunciation:
ta-floo-prost


Trade Name(s)

  • Zioptan

Ther. Class.
ocular hypotensive agent

Pharm. Class.
prostaglandins

Indications

Lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

Action

Acts as a prostaglandin analogues that decreases intraocular pressure by ↑ uveoscleral outflow.

Therapeutic Effect(s):

↓ intraocular pressure.

Pharmacokinetics

Absorption: Absorbed through cornea and is converted to the active metabolite tafluprost acid.

Distribution: Unknown.

Metabolism and Excretion: Further metabolized and eliminated.

Half-life: Unknown.

TIME/ACTION PROFILE (↓ in intraocular pressure)

ROUTEONSETPEAKDURATION
Ophthwithin 2–4 hr12 hr24 hr

Contraindication/Precautions

Contraindicated in:

  • Pedi: Avoid use in children due to unknown safety of chronic ↑ pigmentation.

Use Cautiously in:

  • Aphakia, pseudoaphakia with a torn posterior lens capsule
  • Known risk factors for macular edema
  • OB: Women with child-bearing potential should practice adequate contraception
  • Lactation:Use cautiously in nursing women.

Adverse Reactions/Side Effects

EENT: conjunctival hyperemia, blurred vision, cataract, permanent iris pigmentation, eyelid pigmentation, lash pigmentation/increased thickness/↑ number, macular edema, ocular stinging/irritation

* CAPITALS indicate life-threatening.
Underline indicate most frequent.

Interactions

Drug-Drug

Note noted.

Route/Dosage

Ophth: (Adults) One drop once daily (into conjunctival sac) in the evening into affected eye(s).

Availability

Ophthalmic solution : 0.0015% in 0.3 mL single-use containers

Assessment

  • Measure intraocular pressure periodically during therapy.

Potential Diagnoses

Implementation

  • Ophth: Wash hands prior to instillation. Pull lower lid downward and look up. Instill 1 drop in conjunctival sac each evening. Each unit is for one-time use; discard after using. Store unopened foil pouches in refrigerator. Do not open pouch until ready to use.
    • If used with other ophthalmic medications, administer at least 5 min apart.

Patient/Family Teaching

  • Instruct patient to use drops as directed. Do not use more than 1 drop daily; may increase intraocular pressure. Do not use for a condition for which it was not prescribed. Do not share with others, even if they have the same symptoms; may cause harm.
  • Advise patient to read the Patient Information Leaflet prior to initiating therapy and with each Rx refill in case of changes.
  • Inform patient of potential side effects including brownish color of the iris; may be permanent. Also, darkening of the eyelid, increasing length, thickness, color, or number of eyelashes, and hair growth on eyelids; usually reversible.
  • Advise patient to notify health care professional if eye injury, eye infection, sudden loss of vision, eye surgery, swelling and redness around eye, or problems with eyelids occur.
  • Instruct patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and to consult with health care professional before taking other medications.
  • Advise female patient use adequate contraception during therapy and to notify health care professional if pregnancy is planned or suspected, or if breastfeeding.

Evaluation/Desired Outcomes

Reduction of intraocular pressure.

tafluprost is a sample topic from the Davis's Drug Guide.

To view other topics, please or purchase a subscription.

Anesthesia Central is an all-in-one web and mobile solution for treating patients before, during, and after surgery. This collection of drug, procedures and test information is derived from Davis’s Drug, MGH Clinical Anesthesia Procedures, Pocket Guide to Diagnostic Tests, and MEDLINE Journals. Learn more.

Citation

Quiring, Courtney, et al. "Tafluprost." Davis's Drug Guide, 16th ed., F.A. Davis Company, 2019. Anesthesia Central, anesth.unboundmedicine.com/anesthesia/view/Davis-Drug-Guide/109681/all/tafluprost.
Quiring C, Sanoski CA, Vallerand AH. Tafluprost. Davis's Drug Guide. 16th ed. F.A. Davis Company; 2019. https://anesth.unboundmedicine.com/anesthesia/view/Davis-Drug-Guide/109681/all/tafluprost. Accessed April 24, 2019.
Quiring, C., Sanoski, C. A., & Vallerand, A. H. (2019). Tafluprost. In Davis's Drug Guide. Available from https://anesth.unboundmedicine.com/anesthesia/view/Davis-Drug-Guide/109681/all/tafluprost
Quiring C, Sanoski CA, Vallerand AH. Tafluprost [Internet]. In: Davis's Drug Guide. F.A. Davis Company; 2019. [cited 2019 April 24]. Available from: https://anesth.unboundmedicine.com/anesthesia/view/Davis-Drug-Guide/109681/all/tafluprost.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC T1 - tafluprost ID - 109681 A1 - Quiring,Courtney, AU - Sanoski,Cynthia A, AU - Vallerand,April Hazard, BT - Davis's Drug Guide UR - https://anesth.unboundmedicine.com/anesthesia/view/Davis-Drug-Guide/109681/all/tafluprost PB - F.A. Davis Company ET - 16 DB - Anesthesia Central DP - Unbound Medicine ER -